Evidence-based treatment pathways for translational studies in obsessive- compulsive disorders

Anxiety Disorders

Volumn 29, Issue , 2013, Pages 164-177

  Fineberg, N A ^a,b,c   Pallanti, S ^d,e   Reghunandanan, S ^a  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF FLORENCE   (Italy)

^e MOUNT SINAI HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925855184     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000353618     Document Type: Chapter

References (53)

1. Fineberg NA, Brown A, Reghunandanan S, Pampaloni I. Evidence-based pharmacotherapy of obsessive- compulsive disorder. Int J Neuropsychopharmacol 2012; 15: 1173-1191.
2. Hollander E, Stein D, Fineberg NA, Marteau F, Legault M. Quality of life outcomes in patients with obsessive-compulsive disorder: relationship to treatment response and symptom relapse. J Clin Psychiatry 2010; 71: 784-792.
3. Boschen MJ, Drummond LM, Pillay A. Treatment of severe, treatment-refractory obsessive-compulsive disorder: a study of inpatient and community treatment. CNS Spectr 2008; 13: 1056-1065.
4. Fineberg N, Reghunandanan S, Simpson HB, Phillips K, Richter P, Matthews K, Stein DS, Sareen J, Brown A, Sookman D: Obsessive compulsive disorder (OCD): practical strategies for pharmacological and somatic treatment in adults, submitted.
5. Hollander E, Wong C. Psychosocial function and economic costs of obsessive compulsive disorder. CNS Spectr 1998; 3: 48-58.
6. Insel TS, Voon V, Nye JS, Brown VJ, Altevogt BM, Bullmore ET, Goodwin GM, Howard RJ, Kupfer DJ, Malloch G, Marston HM, Nutt DJ, Robbins TW, Stahl SM, Tricklebank MD, Williams JH, Sahakian BJ: Innovative solutions to novel drug development in mental health. Neurosci Biobehav Rev, in press.
7. Dell'Osso B, Buoli M, Hollander E, Altamura AC:Duration of untreated illness as a predictor of treatment response and remission in obsessive-compulsive disorder. World J Biol Psychiatry 2010; 11: 59-65.
8. Fineberg NA, Baldwin DS, Menchon JM, Denys D, Grünblatt E, Pallanti S, Stein DJ, Zohar J. Manifesto for a European research network into obsessivecompulsive and related disorders. Eur Neuropsychopharmacol 2013; 23: 561-568.
9. Fineberg NA, Potenza MN, Chamberlain SR, Berlin HA, Menzies L, Bechara A, Sahakian BJ, Robbins TW, Bullmore ET, Hollander E. Probing compulsive and impulsive behaviors, from animal models to endophenotypes:a narrative review. Neuropsychopharmacology 2010; 35: 591-604.
10. Chamberlain SR, Menzies L: Neurocognitive angle:the search for endophenotypes; in Zohar J (eds): Obsessive Compulsive Disorder: Current Science and Clinical Practice. Chichester, Wiley-Blackwell, 2012, pp 300-330.
11. Johnston BA, Mwangi B, Matthews K: Predictive classification of individual magnetic resonance imaging scans from children and adolescents. Eur Child Adolesc Psychiatry, E-pub ahead of print.
12. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, Heninger GR, Charney DS. The Yale-Brown Obsessive-Compulsive Scale. 2. Validity. Arch Gen Psychiatry 1989; 46: 1012-1016.
13. Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, Charney DS. The Yale-Brown Obsessive-Compulsive Scale. 1. Development, use, and reliability. Arch Gen Psychiatry 1989; 46: 1006-1011.
14. Storch EA, Murphy TK, Geffken GR, Soto O, Sajid M, Allen P, Roberti JW, Killiany EM, Goodman WK:Psychometric evaluation of the children's Yale-Brown Obsessive-Compulsive scale. Psychiatry Res 2004; 129: 91-98.
15. Phillips KA, Hollander E, Rasmussen SA, Aronowitz BR, DeCaria C, Goodman WK. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacol Bull 1997; 33: 17-22.
16. Black DW, McNeilly DP, Burke WJ, Shaw MC, Allen J. An open-label trial of acamprosate in the treatment of pathological gambling. Ann Clin Psychiatry 2011; 23: 250-256.
17. NIMH Research Domain Criteria (RDoC). www.nimh.nih.gov/research/rdoc/rdoc%20wm%20proceedings.pdf (accessed 20th April 2013).
18. Insel TR, Murphy DL, Cohen RM, Alterman I, Kilts C, Linnoila M. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983; 46: 5-12.
19. Guy W: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976, pp 76-338.
20. Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol 1996; 11: 89-95.
21. Ware JE, Sherbourne CD. The MOS 36-item shortform health survey (SF-36). 1 Conceptual framework and item selection. Med Care 1992; 30: 473-483.
22. Starcevic V, Berle D, Brakoulias V, Sammut P, Moses K, Milicevic D, Hannan A. The nature and correlates of avoidance in obsessive-compulsive disorder. Aust N Z J Psychiatry 2011; 45: 871-879.
23. Chamberlain SR, Blackwell AD, Fineberg NA, Robbins TW, Sahakian BJ. The neuropsychology of obsessive compulsive disorder: the importance of failures in cognitive and behavioral inhibition as candidate and endophenotypic markers. Neurosci Biobehav Rev 2005; 29: 399-419.
24. Dittrich WH, Johansen T, Fineberg NA. Cognitive Assessment Instrument of Obsessions and Compulsions (CAIOC-13) - a new 13-item scale for evaluating functional impairment associated with OCD. Psychiatry Res 2011; 187: 283-290.
25. Mataix-Cols D, Rosario-Campos MC, Leckman JF:A multi-dimensional model of obsessive-compulsive disorder. Am J Psychiatry 2005; 162: 228-238.
26. Abramowitz JS, Tolin DF, Diefenbach GJ. Measuring change in OCD: Sensitivity of the obsessive-compulsive inventory-revised. J Psychopathol Behav Assess 2005; 27: 317-324.
27. Burns GL, Keortge SG, Formea GM, Sternberger LG:Revision of the Padua Inventory of obsessive compulsive disorder symptoms. distinctions between worry, obsessions and compulsions. Behav Res Ther 1996; 34: 163-173.
28. Sternberger LG, Burns GL. Maudsley Obsessive Compulsive Inventory: obsessive-compulsive symptoms in a non-clinical sample. Behav Res Ther 1990; 28: 337-340.
29. Stein DJ, Andersen EW, Tonnoir B, Fineberg N. Escitalopram in obsessive-compulsive disorder: a randomised, placebo-controlled, paroxetine referenced, fixed-dose, 24-week study. Curr Med Res Opin 2007; 23: 701-711.
30. Hollander E, Koran LM, Goodman WK, Greist JH, Ninan PT, Yang H, Li D, Barbato LM. A doubleblind, placebo-controlled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J Clin Psychiatry 2003; 64: 640-647.
31. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, Pato M, Stein D, Zohar J. Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 2002; 5: 181-191.
32. Sookman D, Steketee G: Specialized cognitive behavior therapy for treatment resistant obsessive compulsive disorder; in Sookman D, Leahy R (eds): Treatment Resistant Anxiety Disorders: Resolving Impasses to Symptom Remission. New York, Routledge, 2010, pp 31-74.
33. Fineberg NA, Tonnoir B, Lemming O, Stein DJ. Escitalopram prevents relapse of obsessive compulsive disorder. Eur Neuropsychopharmacol 2007; 17: 430-439.
34. Pallanti S, Grassi G, Cantisani A: Approaches to treatment resistance; in Zohar J (eds): Obsessive Compulsive Disorder: Current Science and Practice. Chichester, Wiley-Blackwell, 2012, pp 99-131.
35. Fineberg NA, Reghunandanan S, Brown A, Pampaloni I. Pharmacotherapy of obsessive-compulsive disorder: evidence-based treatment and beyond. Aust N Z J Psychiatry 2013; 47: 121-141.
36. Koran LM, Hanna GL, Hollander E, et al: Practice guideline for the treatment of patients with obsessivecompulsive disorder. Arlington, American Psychiatric Association, 2007. http//www.psych.org/psych_pract/treatg/pg/prac_guide.cfm (accessed 15th January 2013).
37. Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen HU. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005; 19: 567-596.
38. National Institute of Clinical Excellence (NICE): Obsessive-compulsive disorder: core interventions in the treatment of obsessive-compulsive disorder and body dysmorphic disorder. 2006. http://www. nice.org.uk/nicemedia/pdf/cg031fullguideline.pdf (accessed 19th November 2011).
39. Stein DJ, Carey PD, Lochner C, Seedat S, Fineberg N, Andersen EW. Escitalopram in obsessive-compulsive disorder: response of symptom dimensions to pharmacotherapy. CNS Spectr 2008; 13: 492-498.
40. March JS, Frances A, Kahn DA, Carpenter D. The Expert Consensus Guideline series. Treatment of obsessive- compulsive disorder. J Clin Psychiatry 1997; 58: 1-72.
41. Montgomery SA. Clomipramine in obsessional neurosis:a placebo-controlled trial. Pharmacol Med 1980; 1: 189-192.
42. De Veaugh-Geiss J, Landau P, Katz R. Treatment of obsessive compulsive disorder with clomipramine. Psychiatry Ann 1989; 19: 97-101.
43. Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D. Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials. Int Clin Psychopharmacol 2006; 21: 337-343.
44. Bloch MH, Weisenberger AL, Kelmendi B, Coric V , Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 2006; 11: 622-632.
45. Maina G, Pessina E, Albert U, Bogetto F. 8-week, single- blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessivecompulsive disorder. Eur Neuropsychopharmacol 2008; 18: 364-372.
46. Pampaloni I, Sivakumaran T, Hawley CJ, Al Allaq A, Farrow J, Nelson S, Fineberg NA. High-dose selective serotonin reuptake inhibitors in OCD: a systematic retrospective case notes survey. J Psychopharmacol 2010; 24: 1439-1445.
47. Fineberg NA, Hawley C, Gale T: Are placebo-controlled trials still important for obsessive compulsive disorder? Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 413-422.
48. Geller DA, March J, AACAP Committee on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with obsessive- compulsive disorder. J Am Acad Child Adolesc Psychiatry 2012; 51: 98-113.
49. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
50. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Melvin GA, Greenhill L, Shen S, Mann J. The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 2011; 168: 1266-1277.
51. Thirion B, Pinel P, Meriaux S, Roche A, Dehaene S, Poline JB. Analysis of a large fMRI cohort: statistical and methodological issues for group analyses. Neuroimage 2007; 35: 105-120.
52. Seghier ML, Lee HL, Schofield T, Ellis CL, Price CJ:Inter-subject variability in the use of two different neuronal networks for reading aloud familiar words. Neuroimage 2008; 42: 1226-1236.
53. Patel SR, Simpson HB. Patient preferences for obsessive- compulsive disorder treatment. J Clin Psychiatry 2010; 71: 1434-1439.